drugset / Trial / NCT03671590
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1 trial to evaluate the safety, pharmacokinetics and efficacy of TG-1701, a Bruton's Tyrosine Kinase (BTK) inhibitor in patients with relapsed or refractory B-cell malignancies.
Timeline
- Start
- 2018-09-10
- Primary completion
- 2024-05-21
- Completion
- 2024-05-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EDRALBRUTINIB | Small molecule | — | Oral |
| Subject | Ublituximab | Monoclonal antibody | — | Intravenous |
| Subject | Umbralisib | Small molecule | — | Oral |